Opinion of the Transparency Council – vigabatrinum
At its meeting on 13 January 2025, the Transparency Council adopted opinion No. 8/2025 on the inclusion in reimbursement of medicines containing the active substance vigabatrinum in the scope of indications for use or dosage or method of administration different from those specified in the Summary of Product Characteristics, i.e., paroxysmal conditions in the course of tuberous sclerosis – monotherapy